Effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization among older adults aged ≥65 years during the Delta variant predominance in Japan: The VENUS Study.
Wataru MimuraChieko IshiguroJunko Terada-HirashimaNobuaki MatsunagaShuntaro SatoYurika KawazoeMegumi MaedaFumiko MurataHaruhisa FukudaPublished in: Journal of epidemiology (2023)
BNT162b2 was highly effective against infection, symptomatic infection, and hospitalization in Japan's older adult population aged ≥65 years during the Delta-predominant period.